Observational Study to Observe the Safety of Levemir® Treatment in Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00735501
Recruitment Status : Completed
First Posted : August 15, 2008
Last Update Posted : October 29, 2014
Information provided by (Responsible Party):
Novo Nordisk A/S

Brief Summary:
This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.

Condition or disease Intervention/treatment
Diabetes Diabetes Mellitus, Type 2 Drug: insulin detemir

Study Type : Observational
Actual Enrollment : 314 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Safety of Levemir® (Insulin Detemir) Treatment in Patients With Type 2 Diabetes
Study Start Date : March 2008
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
A Drug: insulin detemir
Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
Other Name: Levemir®

Primary Outcome Measures :
  1. Incidence of serious adverse drug reactions, including major hypoglycaemic events [ Time Frame: After 26 weeks ]

Secondary Outcome Measures :
  1. Number of all hypoglycaemic events [ Time Frame: at 12 weeks and 26 weeks ]
  2. Number of all adverse drug reactions [ Time Frame: after 12 and 26 weeks ]
  3. HbA1c [ Time Frame: at 12 and 26 weeks ]
  4. Variability in fasting plasma glucose (FPG) values and average FPG levels at visits [ Time Frame: at 12 and 26 weeks ]
  5. Weight changes [ Time Frame: at 12 and 26 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients aged 18 or above, with type 2 diabetes, who together with their physician, have decided to switch to Levemir® from human basal insulin treatment

Inclusion Criteria:

  • Any patient with type 2 diabetes
  • Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin)
  • Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient

Exclusion Criteria:

  • Known or suspected allergy to study product(s) or related products.
  • Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00735501

Copenhagen S, Denmark, 2300
Stockholm, Sweden, 182 88
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT00735501     History of Changes
Other Study ID Numbers: NN304-1938
First Posted: August 15, 2008    Key Record Dates
Last Update Posted: October 29, 2014
Last Verified: October 2014

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Detemir
Hypoglycemic Agents
Physiological Effects of Drugs